Results 11 to 20 of about 148,383 (342)

Propranolol in hypertension [PDF]

Postgraduate Medical Journal, 1968
Summary Twenty-four hypertensive patients, eleven of whom had angina pectoris as well, have been treated with propranolol in doses up to 400 mg daily. The thirteen patients without angina received methyldopa 2 g daily in addition to propranolol. A significant reduction of systolic and diastolic blood pressure was found in both groups.
Shakul Tewari, R. H. E. Grant
  +11 more sources

Design and Evaluation of Dissolving Microneedles for Enhanced Dermal Delivery of Propranolol Hydrochloride

Pharmaceutics, 2021
Oral propranolol hydrochloride has been the first-line treatment for infantile hemangioma (IH), whereas systemic exposure to propranolol has the potential of causing serious adverse reactions.
Jingjing He, Zichen Zhang, Xianzi Zheng, Lu Li, Jianping Qi, Wei Wu, Yi Lu   +6 more
doaj   +2 more sources

Propranolol: A 50-year historical perspective

Annals of Indian Academy of Neurology, 2019
Propranolol is a beta-adrenergic receptor antagonist that was developed by the British scientist Sir James Black primarily for the treatment of angina pectoris, more than 50 years ago.
A V Srinivasan
doaj   +2 more sources

Propranolol 0.2% Eye Micro-Drops for Retinopathy of Prematurity: A Prospective Phase IIB Study

Frontiers in Pediatrics, 2019
Background: Oral propranolol reduces retinopathy of prematurity (ROP) progression, although not safely. Propranolol 0.1% eye micro-drops administered to newborns with stage 2 ROP are well-tolerated, but not sufficiently effective.Methods: A multi-center ...
Luca Filippi, Giacomo Cavallaro, Giacomo Cavallaro, Elettra Berti, Letizia Padrini, Gabriella Araimo, Giulia Regiroli, Giulia Regiroli, Genny Raffaeli, Genny Raffaeli, Valentina Bozzetti, Paolo Tagliabue, Barbara Tomasini, Annalisa Mori, Giuseppe Buonocore, Massimo Agosti, Angela Bossi, Gaetano Chirico, Salvatore Aversa, Pina Fortunato, Silvia Osnaghi, Barbara Cavallotti, Martina Suzani, Maurizio Vanni, Giulia Borsari, Simone Donati, Giuseppe Nascimbeni, Daniel Nardo, Stefano Piermarocchi, Giancarlo la Marca, Giulia Forni, Silvano Milani, Ivan Cortinovis, Maura Calvani, Paola Bagnoli, Massimo Dal Monte, Anna Maria Calvani, Alessandra Pugi, Eduardo Villamor, Gianpaolo Donzelli, Fabio Mosca, Fabio Mosca   +41 more
doaj   +2 more sources

Inappropriate use of propranolol among medical and dental students at the University of Jordan: cross-sectional study [PDF]

Frontiers in Medicine
AimThis paper aimed to investigate the prevalence of beta-blocker inappropriate use specifically propranolol, among medical and dental students at the University of Jordan.
Hana Taha, Hana Taha, Suhib Awamleh, AbdelRahman Al Tayyeb, Salwa Samhouri, Yousef Abbasi, Lujaien Alwaked, Aya El Jaber, Raseel Massad, Sireen M. Alkhaldi   +9 more
doaj   +2 more sources

Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression

Scientific Reports, 2018
Propranolol, a widely used non-selective beta-adrenergic receptor blocker, was recently shown to display anticancer properties. Its potential to synergize with certain drugs has been also outlined.
Laura Brohée, Olivier Peulen, Betty Nusgens, Vincent Castronovo, Marc Thiry, Alain C. Colige, Christophe F. Deroanne   +6 more
doaj   +2 more sources

R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma

eLife, 2019
Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma. Despite the clinical benefit of propranolol therapy in hemangioma, the mechanistic understanding of what drives this outcome is limited ...
Jeroen Overman, Frank Fontaine, Jill Wylie-Sears, Mehdi Moustaqil, Lan Huang, Marie Meurer, Ivy Kim Chiang, Emmanuelle Lesieur, Jatin Patel, Johannes Zuegg, Eddy Pasquier, Emma Sierecki, Yann Gambin, Mohamed Hamdan, Kiarash Khosrotehrani, Gregor Andelfinger, Joyce Bischoff, Mathias Francois   +17 more
doaj   +2 more sources

New onset bronchial asthma following oral propranolol for infantile hemangioma [PDF]

Respiratory Medicine Case Reports
Propranolol, a nonselective adrenergic beta-receptor blocker, is the first-line drug used for the treatment of infantile hemangiomas (IH). However, its use is contraindicated in patients with bronchial asthma.
Yuki Yamaguchi, Satoshi Horino, Hiroki Miyabayashi, Haruka Aki, Katsushi Miura   +4 more
doaj   +2 more sources

PROPRANOLOL [PDF]

The Lancet, 1967

openalex   +4 more sources

Efficacy and Safety of Propranolol vs Atenolol in Infants With Problematic Infantile Hemangiomas: A Randomized Clinical Trial.

JAMA Otolaryngology - Head and Neck Surgery, 2021
Importance Propranolol has become the first-line therapy for problematic infantile hemangiomas (IHs) that require systemic therapy. However, different adverse events have been reported during propranolol treatment.
Yi Ji, Siyuan Chen, Kaiying Yang, Xuepeng Zhang, Jiangyuan Zhou, Lizhi Li, B. Xiang, T. Qiu, S. Dai, Xian Jiang, Guo-yan Lu, Liqin Qiu, Feiteng Kong, Yongbo Zhang   +13 more
semanticscholar   +1 more source